PBH Stock Analysis: Prestige Brand Holdings | NYSE

Analgesics, Personal Care, Oral Care, Digestive Health

Total Rating 39

Safety 64

Buy Signal -0.68

Drug Manufacturers - Specialty & Generic
Industry Rotation: -10.4

Market Cap: 2.38B
Avg Turnover: 27.0M

Risk 3d forecast

Volatility36.5%

VaR 5^th Pctl6.48%

VaR vs Median7.70%

Reward TTM

Sharpe Ratio-0.70

Rel. Str. IBD10.9

Rel. Str. Peer Group14

Character TTM

Beta0.137

Beta Downside0.227

Hurst Exponent0.441

Drawdowns 3y

Max DD49.00%

CAGR/Max DD-0.11

CAGR/Mean DD-0.34

EPS (Earnings per Share)

EPS CAGR: 0.89%
EPS Trend: 21.7%

Last SUE: 1.16
Qual. Beats: 1

Revenue

Rev. CAGR: -0.96%
Rev. Trend: -69.8%

Last SUE: 1.60
Qual. Beats: 1

Warnings

Below Avwap Earnings

Below Sma 200d

Tailwinds

Garp

Seasonality 11.6 years of data

Jan -3.2% 17

Feb +4.8% 35

Mar +1.0% 5

Apr -1.1% 32

May -1.3% 28

Jun +2.6% 35

Jul -0.3% 5

Aug -6.2% 28

Sep -3.2% 47

Oct -0.1% 8

Nov +4.2% 28

Dec +1.4% 2

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: PBH Prestige Brand Holdings

Prestige Consumer Healthcare Inc. (NYSE: PBH), formerly Prestige Brands Holdings until its 2018 renaming, is a U.S.-based consumer healthcare company founded in 1996 and headquartered in Tarrytown, New York. It develops, manufactures, and distributes over-the-counter (OTC) health and personal care products across two reporting segments: North American OTC Healthcare and International OTC Healthcare, with operations spanning North America, Australia, and other international markets.

The company operates a brand-portfolio model built around established niche OTC and personal care labels rather than a single pipeline-driven franchise. Its portfolio spans more than a dozen consumer healthcare brands, including analgesics (BC, Goodys), baby care (Boudreauxs Butt Paste), sore throat relief (Chloraseptic), eye care (Clear Eyes, TheraTears), wart removal (Compound W), ear care (Debrox), oral care (DenTek), motion sickness (Dramamine), gastrointestinal health (Fleet, Gaviscon), cough/throat (Ludens), womens health (Monistat, Summers Eve), lice treatment (Nix), and hydration/respiratory care (Fess, Hydralyte).

Distribution is primarily retail, covering mass merchandisers and drug, food, dollar, convenience, and club stores, supplemented by e-commerce channels. As a GICS-classified Pharmaceuticals sub-industry company within Health Care, Prestige competes in the consumer healthcare segment, where products are sold without a prescription and brand equity, shelf placement, and advertising typically drive category share.

Headlines to Watch Out For

North American OTC Healthcare segment revenue trends drive consensus
International segment expansion in Australia and New Zealand boosts margins
Leveraged balance sheet limits capital allocation and buyback flexibility

Piotroski VR-10 (Strict) 4.5

Net Income: 172.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA -2.48 > 1.0
NWC/Revenue: 31.04% < 20% (prev 33.11%; Δ -2.06% < -1%)
CFO/TA 0.06 > 3% & CFO 257.2m > Net Income 172.0m
Net Debt (2.02b) to EBITDA (312.7m): 6.47 < 3
Current Ratio: 3.23 > 1.5 & < 3
Outstanding Shares: last quarter (47.6m) vs 12m ago -4.47% < -2%
Gross Margin: 53.26% > 18% (prev 56.18%; Δ -2.92% > 0.5%)
Asset Turnover: 27.62% > 50% (prev 32.64%; Δ -5.02% > 0%)
Interest Coverage Ratio: 6.08 > 6 (EBIT TTM 280.3m / Interest Expense TTM 46.1m)

Altman Z'' 2.99

A: 0.08 (Total Current Assets 496.8m - Total Current Liabilities 153.8m) / Total Assets 4.57b
B: 0.39 (Retained Earnings 1.78b / Total Assets 4.57b)
C: 0.07 (EBIT TTM 280.3m / Avg Total Assets 4.00b)
D: 0.72 (Book Value of Equity 1.92b / Total Liabilities 2.65b)
Altman-Z'' = 2.99 = A

Beneish M -2.86

DSRI: 1.13 (Receivables 187.4m/168.4m, Revenue 1.10b/1.12b)
GMI: 1.05 (GM 56.18% / 53.26%)
AQI: 1.04 (AQ_t 0.86 / AQ_t-1 0.82)
SGI: 0.99 (Revenue 1.10b / 1.12b)
TATA: -0.02 (NI 172.0m - CFO 257.2m) / TA 4.57b)
Beneish M = -2.86 (Cap -4..+1) = A

What is the price of PBH shares?

As of August 13, 2026, the stock is trading at USD 52.27 with a total of 448,632 shares traded. Over the past week, the price has changed by -1.34%, over one month by +7.04%, over three months by +3.69% and over the past year by -19.97%.

Current recommended Stop Loss: 48.10 (which is 8% or 2.1 ATR below the current price).

Is PBH a buy, sell or hold?

Prestige Brand Holdings has received a consensus analysts rating of 3.71. Therefore, it is recommended to hold PBH.

StrongBuy: 3
Buy: 0
Hold: 3
Sell: 1
StrongSell: 0

What are the forecasts/targets for the PBH price?

Analysts Target Price	66.8	27.8%

Prestige Brand Holdings (PBH) - Fundamental Data Overview as of 08 August 2026

Market Cap USD = 2.38b (2.38b USD * 1.0 USD.USD)
P/E Trailing = 13.9207
P/E Forward = 11.5607
P/S = 2.327
P/B = 1.3051
P/EG = 1.5722
Revenue TTM = 1.10b USD
EBIT TTM = 280.3m USD
EBITDA TTM = 312.7m USD
Long Term Debt = 994.0m USD (from longTermDebt, last fiscal year)
Short Term Debt = 20.2m USD (from shortTermDebt, last quarter)
Debt = 2.11b USD (from shortLongTermDebtTotal, last quarter) + Leases 48.5m
Net Debt = 2.02b USD (calculated: Debt 2.11b - CCE 89.1m)
Enterprise Value = 4.40b USD (2.38b + Debt 2.11b - CCE 89.1m)
Interest Coverage Ratio = 6.08 (Ebit TTM 280.3m / Interest Expense TTM 46.1m)
EV/FCF = 18.11x (Enterprise Value 4.40b / FCF TTM 243.1m)
FCF Yield = 5.52% (FCF TTM 243.1m / Enterprise Value 4.40b)
FCF Margin = 22.01% (FCF TTM 243.1m / Revenue TTM 1.10b)
Net Margin = 15.57% (Net Income TTM 172.0m / Revenue TTM 1.10b)
Gross Margin = 53.26% ((Revenue TTM 1.10b - Cost of Revenue TTM 516.4m) / Revenue TTM)
Gross Margin QoQ = 51.25% (prev 50.02%)
Tobins Q-Ratio = 0.96 (Enterprise Value 4.40b / Total Assets 4.57b)
Interest Expense / Debt = 2.18% (Interest Expense 46.1m / Debt 2.11b)
Taxrate = 26.57% (62.2m / 234.3m)
NOPAT = 205.8m (EBIT 280.3m * (1 - 26.57%))
Current Ratio = 3.23 (Total Current Assets 496.8m / Total Current Liabilities 153.8m)
Debt / Equity = 1.10 (Debt 2.11b / totalStockholderEquity, last quarter 1.92b)
Debt / EBITDA = 6.47 (Net Debt 2.02b / EBITDA 312.7m)
Debt / FCF = 8.32 (Net Debt 2.02b / FCF TTM 243.1m)
Total Stockholder Equity = 1.86b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.30% (Net Income 172.0m / Total Assets 4.57b)
RoE = 9.22% (Net Income TTM 172.0m / Total Stockholder Equity 1.86b)
RoCE = 9.81% (EBIT 280.3m / Capital Employed (Equity 1.86b + L.T.Debt 994.0m))
RoIC = 4.70% (NOPAT 205.8m / Invested Capital 4.38b)
WACC = 4.18% (E(2.38b)/V(4.49b) * Re(6.47%) + D(2.11b)/V(4.49b) * Rd(2.18%) * (1-Tc(0.27)))
Discount Rate = 6.47% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.28 | Cagr: -2.43%
[DCF] Terminal Value 74.09% ; FCFF base≈253.0m ; Y1≈234.4m ; Y5≈211.3m
[DCF] Fair Price = 27.94 (EV 3.35b - Net Debt 2.02b = Equity 1.32b / Shares 47.4m; r=8.35% [WACC [floored]]; 5y FCF grow -9.22% → 2.50% )
EPS Correlation: 21.66 | EPS CAGR: 0.89% | SUE: 1.16 | # QB: 1
Revenue Correlation: -69.79 | Revenue CAGR: -0.96% | SUE: 1.60 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.20 | Chg30d=+3.91% | Revisions=-25% | Analysts=2
EPS current Year (2027-03-31): EPS=4.61 | Chg30d=+0.00% | Revisions=-70% | GrowthEPS=+5.2% | GrowthRev=+12.9%
EPS next Year (2028-03-31): EPS=4.98 | Chg30d=-1.73% | Revisions=-25% | GrowthEPS=+8.2% | GrowthRev=+7.6%
[Analyst] Revisions Ratio: -75% (up=0, down=9)